Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nowak, A. K.
Right arrow Articles by Lake, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nowak, A. K.
Right arrow Articles by Lake, R. A.
[Cancer Research 63, 4490-4496, August 1, 2003]
© 2003 American Association for Cancer Research

Immunology

Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors1

Anna K. Nowak, Bruce W. S. Robinson and Richard A. Lake2

University Department of Medicine, Western Australian Institute for Medical Research, Queen Elizabeth II Medical Centre, Nedlands, Perth, Western Australia 6009

Cytotoxic chemotherapy is generally considered immunosuppressive, with neutropenia and lymphopenia being common adverse side effects. In this context, we have shown previously that the cytidine analogue, gemcitabine, abolishes humoral responses but, in contrast, augments antigen-specific cellular antitumor immunity. This augmentation occurs in the context of increased antigen cross-presentation, T lymphocyte expansion, and infiltration of the tumor. Here, we combine an immunotherapy (CD40 ligation using FGK45; 100 µg; i.p., q2dx3) with gemcitabine (120 µg/gram; i.p.; q3dx5) to treat established solid tumors. This protocol induced long-term cures in <=80% of mice, and all of the cured mice were resistant to tumor rechallenge. Synergy between the drug and immunotherapy could not be established in vitro and was only seen in the context of tumor cell death. It was associated with an increase in both CD4 and CD8 T-cell infiltration of the tumor, but depletion studies clearly showed that CD4 T cells were not a necessary component of the cure. In contrast, CD8 T cells were absolutely required for the success of this treatment regimen. The priming effect of gemcitabine was not limited to debulking, because mice resected to an equivalent, or lesser residual tumor volume did not eradicate tumor with subsequent immunotherapy. This study provides evidence that chemotherapy has the capacity to augment cellular antitumor immunity, a finding with wider implications for the management of treatment-resistant solid tumors.




This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
A. Soeda, Y. Morita-Hoshi, H. Makiyama, C. Morizane, H. Ueno, M. Ikeda, T. Okusaka, S. Yamagata, N. Takahashi, I. Hyodo, et al.
Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer
Jpn. J. Clin. Oncol., October 1, 2009; (2009) hyp112v1.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Tanaka, H. Matsushima, A. Nishibu, B. E. Clausen, and A. Takashima
Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
Cancer Res., September 1, 2009; 69(17): 6987 - 6994.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Menard, J.-Y. Blay, C. Borg, S. Michiels, F. Ghiringhelli, C. Robert, C. Nonn, N. Chaput, J. Taieb, N. F. Delahaye, et al.
Natural Killer Cell IFN-{gamma} Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
Cancer Res., April 15, 2009; 69(8): 3563 - 3569.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
M. NAKAMURA, J. WADA, H. SUZUKI, M. TANAKA, M. KATANO, and T. MORISAKI
Long-term Outcome of Immunotherapy for Patients with Refractory Pancreatic Cancer
Anticancer Res, March 1, 2009; 29(3): 831 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. H. Kim, B. K. Choi, H. S. Oh, W. J. Kang, R. S. Mittler, and B. S. Kwon
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Mol. Cancer Ther., February 1, 2009; 8(2): 469 - 478.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. de la Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. Codes-Manuel de Villena
Cancer and Immune Response: Old and New Evidence for Future Challenges
Oncologist, December 1, 2008; 13(12): 1246 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
C. Jackaman, A. M. Lew, Y. Zhan, J. E. Allan, B. Koloska, P. T. Graham, B. W. S. Robinson, and D. J. Nelson
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
Int. Immunol., November 1, 2008; 20(11): 1467 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. H. Kim, B. K. Choi, K. H. Kim, S. W. Kang, and B. S. Kwon
Combination Therapy with Cisplatin and Anti-4-1BB: Synergistic Anticancer Effects and Amelioration of Cisplatin-Induced Nephrotoxicity
Cancer Res., September 15, 2008; 68(18): 7264 - 7269.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. De Vleeschouwer, S. Fieuws, S. Rutkowski, F. Van Calenbergh, J. Van Loon, J. Goffin, R. Sciot, G. Wilms, P. Demaerel, M. Warmuth-Metz, et al.
Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
Clin. Cancer Res., May 15, 2008; 14(10): 3098 - 3104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Morris, C. Platell, and B. Iacopetta
Tumor-Infiltrating Lymphocytes and Perforation in Colon Cancer Predict Positive Response to 5-Fluorouracil Chemotherapy
Clin. Cancer Res., March 1, 2008; 14(5): 1413 - 1417.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Y. Zhang, L. Xiang, R. Hassan, and I. Pastan
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors
PNAS, October 23, 2007; 104(43): 17099 - 17104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Zhong, B. Han, I. L. Tourkova, A. Lokshin, A. Rosenbloom, M. R. Shurin, and G. V. Shurin
Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth
Clin. Cancer Res., September 15, 2007; 13(18): 5455 - 5462.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
Gut, September 1, 2007; 56(9): 1275 - 1282.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. M. Wall, K. Milne, M. L. Martin, P. H. Watson, P. Theiss, and B. H. Nelson
Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells
Cancer Res., July 1, 2007; 67(13): 6442 - 6450.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. A. Manning, J. G.M. Ullman, J. M. Leatherman, J. M. Asquith, T. R. Hansen, T. D. Armstrong, D. J. Hicklin, E. M. Jaffee, and L. A. Emens
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism
Clin. Cancer Res., July 1, 2007; 13(13): 3951 - 3959.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. H. Vonderheide
Prospect of Targeting the CD40 Pathway for Cancer Therapy
Clin. Cancer Res., February 15, 2007; 13(4): 1083 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Gamrekelashvili, C. Kruger, R. von Wasielewski, M. Hoffmann, K. M. Huster, D. H. Busch, M. P. Manns, F. Korangy, and T. F. Greten
Necrotic Tumor Cell Death In Vivo Impairs Tumor-Specific Immune Responses
J. Immunol., February 1, 2007; 178(3): 1573 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. H. Kang, J. H. Lee, C. K. Song, H. D. Han, B. C. Shin, S. I. Pai, C.-F. Hung, C. Trimble, J.-S. Lim, T. W. Kim, et al.
Epigallocatechin-3-Gallate Enhances CD8+ T Cell-Mediated Antitumor Immunity Induced by DNA Vaccination
Cancer Res., January 15, 2007; 67(2): 802 - 811.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H.M.G.M. den Brok, R. P.M. Sutmuller, S. Nierkens, E. J. Bennink, L. W.J. Toonen, C. G. Figdor, T. J.M. Ruers, and G. J. Adema
Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine.
Cancer Res., July 15, 2006; 66(14): 7285 - 7292.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, Y. Hayakawa, E. Cretney, N. Zerafa, P. Sivakumar, H. Yagita, and K. Takeda
IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy
J. Immunol., May 15, 2006; 176(10): 6347 - 6355.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. G. van der Most, A. Currie, B. W.S. Robinson, and R. A. Lake
Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity
Cancer Res., January 15, 2006; 66(2): 601 - 604.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Correale, M. G. Cusi, K. Y. Tsang, M. T. Del Vecchio, S. Marsili, M. L. Placa, C. Intrivici, A. Aquino, L. Micheli, C. Nencini, et al.
Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients
J. Clin. Oncol., December 10, 2005; 23(35): 8950 - 8958.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. W. Robinson and R. A. Lake
Advances in malignant mesothelioma.
N. Engl. J. Med., October 13, 2005; 353(15): 1591 - 1603.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Broomfield, A. Currie, R. G. van der Most, M. Brown, I. van Bruggen, B. W.S. Robinson, and R. A. Lake
Partial, but not Complete, Tumor-Debulking Surgery Promotes Protective Antitumor Memory when Combined with Chemotherapy and Adjuvant Immunotherapy
Cancer Res., September 1, 2005; 65(17): 7580 - 7584.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Correale*, M. G. Cusi, M. T. Del Vecchio, A. Aquino, S. Prete, K. Y. Tsang, L. Micheli, C. Nencini, M. La Placa*, F. Montagnani*, et al.
Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro
J. Immunol., July 15, 2005; 175(2): 820 - 828.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Casati, V. S. Zimmermann, F. Benigni, M. T. S. Bertilaccio, M. Bellone, and A. Mondino
The Immunogenicity of Dendritic Cell-Based Vaccines Is Not Hampered by Doxorubicin and Melphalan Administration
J. Immunol., March 15, 2005; 174(6): 3317 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. J. D. van Mierlo, Z. F. H. M. Boonman, H. M. H. Dumortier, A. Th. den Boer, M. F. Fransen, J. Nouta, E. I. H. van der Voort, R. Offringa, R. E. M. Toes, and C. J. M. Melief
Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication
J. Immunol., December 1, 2004; 173(11): 6753 - 6759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Suzuki, V. Kapoor, H.-K. Cheung, L. E. Ling, P. A. DeLong, L. R. Kaiser, and S. M. Albelda
Soluble Type II Transforming Growth Factor-{beta} Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity
Clin. Cancer Res., September 1, 2004; 10(17): 5907 - 5918.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.